Dr Graf-Schiller elected to the BPI Federal Executive Board

“The diversity of companies and therapeutic disciplines represented in the BPI is a great strength of the association, because we can only meet the major challenges affecting health through interdisciplinary cooperation.”
In November 2023, the Managing Director of SaluVet GmbH, Dr Sandra Graf-Schiller, was elected to the BPI Federal Executive Board. Dr Graf-Schiller wants to give companies that are also active in the veterinary sector a voice and sees the association’s work as an opportunity to make a difference at a political level. To achieve this, the companies must join forces, pool expertise, speak with one voice and thus be a serious partner.
The German Pharmaceutical Industry Association (BPI) represents the interests of around 260 pharmaceutical and biotech companies (human and veterinary) in Germany with approximately 70,000 employees. The BPI member companies (start-ups, SMEs and multinationals) are active in various areas. The products come from the areas of chemically defined active ingredients, biotechnological medicinal products, herbal medicinal products, homeopathic medicinal products and anthroposophic medicinal products.
The interview with Dr Graf-Schiller can be found in the Pharma|report.